
    
      A multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial.
      The on-treatment period is 4 weeks with weekly visits to the clinic, followed by a 4-week
      safety follow-up period after the last dose of ACP-196/placebo. The study was to evaluate the
      safety, PK, PD, and efficacy of ACP-196 in subjects with Rheumatoid Arthritis on background
      Methotrexate
    
  